Evidence map›Paper›PMID 40522768›Full record

SynthesisAnnals of medicine2025

Prevalence of genetic alterations in basal cell carcinoma patients resistant to Hedgehog pathway inhibitors: a systematic review.

Suvijak Untaaveesup, Pornteera Srichana, Gynna Techataweewan, Chanamon Pongphaew, Wichapol Dendumrongsup, Ben Ponvilawan, Nichanant Nampipat, Chanin Limwongse

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Suvijak UntaaveesupChao Khun Paiboon Hospital, Kanchanaburi, Thailand.ORCID 0009-0001-8954-7824
Pornteera SrichanaDetudom Crown Prince Hospital, Ubon Ratchathani, Thailand.ORCID 0009-0000-4403-2002
Gynna TechataweewanFaculty of Medicine, Burapha University Hospital, Burapha University, Chonburi, Thailand.ORCID 0009-0004-7833-9589
Chanamon PongphaewPrincess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok, Thailand.ORCID 0009-0000-5623-6598
Wichapol DendumrongsupFaculty of Medicine, Chulalongkorn University, Bangkok, Thailand.ORCID 0009-0002-5379-5217
Ben PonvilawanDepartment of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.ORCID 0000-0002-0157-7720
Nichanant NampipatDepartment of Medicine, Medical Oncology Unit, Maha Vajiralongkorn Thanyaburi Hospital, Pathum Thani, Thailand.ORCID 0009-0005-8366-3508
Chanin LimwongseDepartment of Medicine, Division of Medical Genetics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-7374-6765

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBasal cell carcinoma (BCC) is a prevalent form of skin cancer that can be localized or metastatic. Current evidence supports the use of Hedgehog (Hh) pathway inhibitors for locally advanced or metastatic BCC with resistance due to genetic alterations in the Hh pathway. This systematic review evaluated the prevalence of genetic alterations in Hh pathway genes in BCC. MATERIALS AND

methodsWe conducted a comprehensive search across four databases: PubMed, EMBASE, SCOPUS and the Cochrane Library. We included articles reporting genetic alterations in patients with locally advanced or metastatic BCC resistant to Hh pathway inhibitors.

resultsWe included three prospective cohort studies encompassing 27 samples, all of which were resistant to vismodegib treatment. The most prevalent genetic mutations in the Hh pathway were in

conclusionsThis systematic review highlights the prevalence of genetic alterations in the Hh pathway in BCC and offers insights into the mechanisms involved in treatment resistance. Understanding the high resistance rates of these genes may facilitate the development of more effective targeted therapies for BCC.

Indexed as

Antineoplastic AgentsBasal Cell CarcinomaDrug Resistance, NeoplasmHedgehog ProteinsSkin NeoplasmsAnilidesHumansMutationPatched-1 ReceptorPrevalencePyridinesSignal TransductionSmoothened ReceptorTumor Suppressor Protein p53AnilidesAntineoplastic AgentsHedgehog ProteinsHhAntag691Patched-1 ReceptorPTCH1 protein, humanPyridinesSmoothened ReceptorSMO protein, humanTP53 protein, humanTumor Suppressor Protein p53Basal cell carcinomagenetic alterationHedgehog pathway inhibitorprevalencesystematic review

Identifiers

PMID40522768
PMCPMC12172076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.